{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:42:22Z","timestamp":1792510942647,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["painmanagementnursing.org","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pain Management Nursing"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.pmn.2025.01.007","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T21:54:34Z","timestamp":1739483674000},"page":"249-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacological Treatment of Chemotherapy-Induced Neuropathy: A Systematic Review of Randomized Clinical Trials"],"prefix":"10.1016","volume":"26","author":[{"given":"Ana Carolina de","family":"Jesus Palma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1701-5279","authenticated-orcid":false,"given":"C\u00e9sar Romero","family":"Antunes J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4688-8857","authenticated-orcid":false,"given":"Eduardo Silva Reis","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Borges","family":"Alencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Karla do Nascimento","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa Maria de Cerqueira","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane Elze Falc\u00e3o","family":"Lins-Kusterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana Maria Torres de Araujo","family":"Azi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6561-6584","authenticated-orcid":false,"given":"Durval Campos","family":"Kraychete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pmn.2025.01.007_bib0001","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sc.2016.123","article-title":"Effectiveness of amitriptyline and lamotrigine in traumatic spinal cord injury-induced neuropathic pain: A randomized longitudinal comparative study","volume":"55","author":"Agarwal","year":"2017","journal-title":"Spinal Cord"},{"issue":"5","key":"10.1016\/j.pmn.2025.01.007_bib0002","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/AJP.0b013e3181cb406e","article-title":"Evaluation of efficacy of the perioperative administration of venlafaxine or gabapentin on acute and chronic postmastectomy pain","volume":"26","author":"Amr","year":"2010","journal-title":"The Clinical Journal of Pain"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0003","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/jrms.JRMS_1068_17","article-title":"The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: A randomized clinical trial","volume":"23","author":"Avan","year":"2018","journal-title":"Journal of Research in Medical Sciences"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/brb3.558","article-title":"Chemotherapy-induced neuropathies-a growing problem for patients and health care providers","volume":"7","author":"Banach","year":"2017","journal-title":"Brain and Behavior"},{"issue":"6","key":"10.1016\/j.pmn.2025.01.007_bib0005","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00520-010-0911-0","article-title":"A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA","volume":"19","author":"Barton","year":"2011","journal-title":"Supportive Care in Cancer"},{"issue":"4","key":"10.1016\/j.pmn.2025.01.007_bib0006","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.biopha.2012.01.002","article-title":"The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: A retrospective study","volume":"66","author":"Chen","year":"2012","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/j.pain.0000000000001540","article-title":"Chemotherapy-induced peripheral neuropathy: where are we now?","volume":"160","author":"Colvin","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.pmn.2025.01.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/26323524241266603","article-title":"Novel drug treatments for pain in advanced cancer and serious illness: A focus on neuropathic pain and chemotherapy-induced peripheral neuropathy","volume":"18","author":"Davis","year":"2024","journal-title":"Palliative Care and Social Practice"},{"issue":"4","key":"10.1016\/j.pmn.2025.01.007_bib0009","first-page":"268","article-title":"Hyperprolactinemia and galactorrhoea with duloxetine in neuropathic pain management","volume":"33","author":"Derle","year":"2019","journal-title":"The Journal of The Turkish Society of Algology"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0010","first-page":"100","article-title":"Nortriptyline for neuropathic pain in adults","volume":"1","author":"Derry","year":"2015","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pmn.2025.01.007_bib0011","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2147\/JPR.S409580","article-title":"Nursing dilemmas in chemotherapy-induced peripheral neuropathy: A qualitative study of a tertiary hospital in China","volume":"16","author":"Fan","year":"2023","journal-title":"Journal of Pain Research"},{"issue":"5","key":"10.1016\/j.pmn.2025.01.007_bib0012","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00280-018-3664-y","article-title":"Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy","volume":"82","author":"Farshchian","year":"2018","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"4","key":"10.1016\/j.pmn.2025.01.007_bib0013","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000491524","article-title":"Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review","volume":"87","author":"Fava","year":"2018","journal-title":"Psychotherapy and Psychosomatics"},{"issue":"10","key":"10.1016\/j.pmn.2025.01.007_bib0014","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s10072-017-3035-1","article-title":"Tapentadol in neuropathic pain cancer patients: A prospective open label study","volume":"38","author":"Gali\u00e8","year":"2017","journal-title":"Neurological Sciences"},{"issue":"7","key":"10.1016\/j.pmn.2025.01.007_bib0015","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00520-014-2158-7","article-title":"A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study of 462 cancer survivors","volume":"22","author":"Gewandter","year":"2014","journal-title":"Supportive Care in Cancer"},{"issue":"4","key":"10.1016\/j.pmn.2025.01.007_bib0016","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3390\/toxins13040235","article-title":"Tetrodotoxin for chemotherapy-induced neuropathic pain: A randomized, double-blind, placebo-controlled, parallel-dose finding trial","volume":"13","author":"Goldlust","year":"2021","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0017","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0304-3959(02)00047-7","article-title":"Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy","volume":"98","author":"Hammack","year":"2002","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/2055102919832234","article-title":"A new normal with chemobrain\u201d: Experiences of the impact of chemotherapy-related cognitive deficits in long-term breast cancer survivors","volume":"6","author":"Henderson","year":"2019","journal-title":"Health Psychology Open"},{"issue":"20","key":"10.1016\/j.pmn.2025.01.007_bib0019","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.2012.44.8738","article-title":"Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy","volume":"31","author":"Hershman","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"oct18 2","key":"10.1016\/j.pmn.2025.01.007_bib0020","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.pmn.2025.01.007_bib0021","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/j.pain.0000000000001577","article-title":"Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: A randomized, placebo-controlled, crossover study","volume":"160","author":"Hincker","year":"2019","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.pmn.2025.01.007_bib0022","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s10147-015-0810-y","article-title":"Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: A pilot randomized trial","volume":"20","author":"Hirayama","year":"2015","journal-title":"International Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.pmn.2025.01.007_bib0023","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/md21050316","article-title":"Efficacy and security of tetrodotoxin in the treatment of cancer-related pain: systematic review and meta-analysis","volume":"21","author":"Huerta","year":"2023","journal-title":"Marine Drugs"},{"issue":"6","key":"10.1016\/j.pmn.2025.01.007_bib0024","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1177\/02692163221085855","article-title":"Pharmacovigilance in hospice\/palliative care: net effect of amitriptyline or nortriptyline on neuropathic pain: UTS\/IMPACCT rapid programme international consecutive cohort","volume":"36","author":"Hussein","year":"2022","journal-title":"Palliative Medicine"},{"issue":"12","key":"10.1016\/j.pmn.2025.01.007_bib0025","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.4103\/jfmpc.jfmpc_1296_20","article-title":"Duloxetine-induced hyponatraemia in a patient with hypocortisolaemia","volume":"9","author":"Ikeguchi","year":"2020","journal-title":"Journal of Family Medicine and Primary Care"},{"key":"10.1016\/j.pmn.2025.01.007_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.682244","article-title":"Different drugs for the treatment of painful diabetic peripheral neuropathy: A meta-analysis","volume":"12","author":"Jingxuan","year":"2021","journal-title":"Frontiers in Neurology"},{"issue":"5","key":"10.1016\/j.pmn.2025.01.007_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.soncn.2024.151685","article-title":"Exploring chemotherapy-induced peripheral neuropathy management practice patterns among oncology clinicians","volume":"40","author":"Kanzawa-Lee","year":"2024","journal-title":"Seminars in Oncology Nursing"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0028","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpainsymman.2007.02.043","article-title":"Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms","volume":"35","author":"Kautio","year":"2008","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1016\/j.pmn.2025.01.007_bib0029","first-page":"109","article-title":"DN4 questionnaire as a useful tool for evaluating the pharmacotherapeutic response to opioid pharmacotherapy in malignant neuropathy","volume":"79","author":"Krtinic","year":"2024","journal-title":"Pharmazie"},{"issue":"5","key":"10.1016\/j.pmn.2025.01.007_bib0030","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s00520-015-3009-x","article-title":"Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: A single-center retrospective case-control study","volume":"24","author":"Kus","year":"2016","journal-title":"Supportive Care in Cancer"},{"issue":"5","key":"10.1016\/j.pmn.2025.01.007_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2024.151724","article-title":"Neurotoxicity in cancer survivorship: the significance of cancer-related cognitive impairment and chemotherapy-induced peripheral neuropathy","volume":"40","author":"Lavoie Smith","year":"2024","journal-title":"Seminars in Oncology Nursing"},{"key":"10.1016\/j.pmn.2025.01.007_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fchem.2024.1447312","article-title":"Recent research progress in tetrodotoxin detection and quantitative analysis methods","volume":"12","author":"Lin","year":"2024","journal-title":"Frontiers in Chemistry"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jnci\/djz088","article-title":"Neuronal protection for chemotherapy neuropathy prevention?","volume":"112","author":"Loprinzi","year":"2020","journal-title":"Journal of the National Cancer Institute"},{"issue":"28","key":"10.1016\/j.pmn.2025.01.007_bib0034","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.pmn.2025.01.007_bib0035","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s00520-016-3177-3","article-title":"Scrambler therapy for the management of chronic pain","volume":"24","author":"Majithia","year":"2016","journal-title":"Supportive Care in Cancer"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0036","first-page":"130","article-title":"Efficacy and safety of gabapentin and pregabalin in chemotherapy-induced peripheral neuropathy","volume":"14","author":"Manjushree","year":"2021","journal-title":"Asian Journal of Pharmaceutical and Clinical Research"},{"key":"10.1016\/j.pmn.2025.01.007_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m1315","article-title":"Pregabalin and gabapentin for pain","author":"Mathieson","year":"2020","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.pmn.2025.01.007_bib0038","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3390\/life14080991","article-title":"Chemotherapy-induced peripheral neuropathy: A recent update on pathophysiology and treatment","volume":"14","author":"Mattar","year":"2024","journal-title":"Life"},{"issue":"2","key":"10.1016\/j.pmn.2025.01.007_bib0039","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s11764-017-0662-8","article-title":"Impact of chemotherapy-induced neurotoxicities on adult cancer survivors\u2019 symptom burden and quality of life","volume":"12","author":"Miaskowski","year":"2018","journal-title":"Journal of Cancer Survivorship"},{"issue":"5","key":"10.1016\/j.pmn.2025.01.007_bib0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neurol.2020.01.361","article-title":"Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations","volume":"176","author":"Moisset","year":"2020","journal-title":"Revue Neurologique"},{"issue":"8","key":"10.1016\/j.pmn.2025.01.007_bib0041","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00520-014-2255-7","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review","volume":"22","author":"Mols","year":"2014","journal-title":"Supportive Care in Cancer"},{"issue":"14","key":"10.1016\/j.pmn.2025.01.007_bib0042","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.clinthera.2011.01.014","article-title":"Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: A 10-week, randomized, double-blind, placebo-controlled, multicenter study","volume":"32","author":"Moon","year":"2010","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pmn.2025.01.007_bib0043","doi-asserted-by":"crossref","DOI":"10.1177\/02692163241267152","article-title":"A peripherally acting \u03bc-opioid receptor antagonist for treating opioid-associated tinnitus: A case report","author":"Ogawa","year":"2024","journal-title":"Palliative Medicine"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0044","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Systematic Reviews"},{"issue":"29","key":"10.1016\/j.pmn.2025.01.007_bib0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.pmn.2025.01.007_bib0046","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpsychires.2020.02.022","article-title":"Duloxetine and cardiovascular adverse events: A systematic review and meta-analysis","volume":"124","author":"Park","year":"2020","journal-title":"Journal of Psychiatric Research"},{"issue":"11","key":"10.1016\/j.pmn.2025.01.007_bib0047","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/jnnp-2021-328323","article-title":"Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence","volume":"94","author":"Park","year":"2023","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0048","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5455\/msm.2023.35.42-47","article-title":"Pregabalin in the treatment of peripheral and central chronic neuropathic pain","volume":"35","author":"Prnjavorac","year":"2023","journal-title":"Materia Socio Medica"},{"issue":"12","key":"10.1016\/j.pmn.2025.01.007_bib0049","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1002\/cncr.23482","article-title":"Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled trial, N01C3","volume":"112","author":"Rao","year":"2008","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.pmn.2025.01.007_bib0050","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.pmn.2025.01.007_bib0051","first-page":"192","article-title":"Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial","volume":"19","author":"Razazian","year":"2014","journal-title":"Neurosciences"},{"issue":"6","key":"10.1016\/j.pmn.2025.01.007_bib0052","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011265.pub2","article-title":"Acetyl-l-carnitine for the treatment of diabetic peripheral neuropathy","volume":"2019","author":"Rolim","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1016\/j.pmn.2025.01.007_bib0053","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1007\/s00520-018-4618-y","article-title":"High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies","volume":"27","author":"Rossignol","year":"2019","journal-title":"Supportive Care in Cancer"},{"issue":"3","key":"10.1016\/j.pmn.2025.01.007_bib0054","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40261-019-00882-6","article-title":"Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: A randomized controlled trial","volume":"40","author":"Salehifar","year":"2020","journal-title":"Clinical Drug Investigation"},{"issue":"16","key":"10.1016\/j.pmn.2025.01.007_bib0055","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.3390\/cancers14164002","article-title":"Comparative efficacy of tapentadol versus tapentadol plus duloxetine in patients with chemotherapy-induced peripheral neuropathy (CIPN): A randomized non-inferiority clinical trial","volume":"14","author":"Sansone","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.pmn.2025.01.007_bib0056","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp-2017-317215","article-title":"Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort","volume":"89","author":"Shah","year":"2018","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"13","key":"10.1016\/j.pmn.2025.01.007_bib0057","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.pmn.2025.01.007_bib0058","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/jgs.15966","article-title":"Adverse effects of pharmacologic treatments of major depression in older adults","volume":"67","author":"Sobieraj","year":"2019","journal-title":"Journal of the American Geriatrics Society"},{"issue":"6","key":"10.1016\/j.pmn.2025.01.007_bib0059","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: A current review","volume":"81","author":"Staff","year":"2017","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pmn.2025.01.007_bib0060","first-page":"l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"6","key":"10.1016\/j.pmn.2025.01.007_bib0061","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.3892\/etm.2016.3871","article-title":"A prospective study to evaluate the efficacy and safety of oral acetyl-l-carnitine for the treatment of chemotherapy-induced peripheral neuropathy","volume":"12","author":"Sun","year":"2016","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"1","key":"10.1016\/j.pmn.2025.01.007_bib0062","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CAD.0000000000001005","article-title":"Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: A real world, open-label experience","volume":"32","author":"Velasco","year":"2021","journal-title":"Anti-Cancer Drugs"},{"issue":"8","key":"10.1016\/j.pmn.2025.01.007_bib0063","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.2337\/dc13-2291","article-title":"A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy","volume":"37","author":"Vinik","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pmn.2025.01.007_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2022.1080888","article-title":"Treatment for chemotherapy-induced peripheral neuropathy: A systematic review of randomized control trials","volume":"13","author":"Wang","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"5","key":"10.1016\/j.pmn.2025.01.007_bib0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/rapm-2019-101207","article-title":"Serotonin\u2013norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: A systematic review and meta-analysis","volume":"45","author":"Wang","year":"2020","journal-title":"Regional Anesthesia & Pain Medicine"},{"issue":"6","key":"10.1016\/j.pmn.2025.01.007_bib0066","first-page":"100","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1016\/j.pmn.2025.01.007_bib0067","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00520-011-1237-2","article-title":"Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study","volume":"20","author":"Yang","year":"2012","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.pmn.2025.01.007_bib0068","article-title":"Insights into the pathogenesis and treatment of chemotherapy-induced neuropathy: A focus on oxidative stress and neuroinflammation","author":"Yu","year":"2024","journal-title":"Current Reviews in Clinical and Experimental Pharmacology"},{"issue":"6","key":"10.1016\/j.pmn.2025.01.007_bib0069","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pmn.2025.01.007_bib0070","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.eclinm.2021.101157","article-title":"Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial","volume":"41","author":"Zhou","year":"2021","journal-title":"EClinicalMedicine"}],"container-title":["Pain Management Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1524904225000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1524904225000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T17:27:39Z","timestamp":1747848459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1524904225000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1524904225000207"],"URL":"https:\/\/doi.org\/10.1016\/j.pmn.2025.01.007","relation":{},"ISSN":["1524-9042"],"issn-type":[{"value":"1524-9042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Treatment of Chemotherapy-Induced Neuropathy: A Systematic Review of Randomized Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Pain Management Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmn.2025.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pain Management Nursing. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}